OKYO Pharma’s (OKYO) “Buy” Rating Reaffirmed at HC Wainwright

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 455.56% from the company’s previous close. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Stock Performance

NASDAQ OKYO opened at $1.26 on Thursday. The company has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.24. OKYO Pharma has a 12-month low of $0.81 and a 12-month high of $2.12.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.